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This is a response to the letter by Romanens et al. [1],
which commented on our paper investigating statin treat-
ment and low-density lipoprotein target value achievement
in Swiss general practice [2]. Romanens et al. raise impor-
tant points, which we are glad to reply to as follows.
First, Romanens et al. point out that new European Society
of Cardiology (ESC) / European Atherosclerosis Society
(EAS) dyslipidaemia guidelines were published in 2019
[3] and their impact on treatment recommendations would
be interesting. We very much agree with this assessment
and dedicated a separate study to this research question [4].
In short, we found that even though the new guidelines re-
duced the cardiovascular risk category from “very high”
to “high” in many patients, it still intensified treatment
recommendations for 71.4% of patients by decreasing the
low-density lipoprotein target values.
Second, Romanens et al. highlight that our study did not
consider Systematic Coronary Risk Evaluation (SCORE)
values for risk classification. Although it would have been
feasible to include this in our study, it would have been
against the recommendation of the 2016 ESC/EAS guide-
lines [5], which explicitly state that SCORE values are on-
ly valid for treatment-naive patients, which our study pop-
ulation was not. Accordingly, we were quite surprised by
speculations raised by Romanens et al. that the absence
of the SCORE in our study is due to influence exerted
by the Swiss Medical Board (SMB). Our above-mentioned
further study on the impact of the new guidelines, which
was also funded by the SMB, considered operationalised
SCORE values and gives corresponding insights to the in-
terested readership. In addition, we are currently conduct-
ing a study precisely dedicated to treatment-naive patients
with assessed cardiovascular risk and expect results to be
published next year.
Romanens et al. see the SMB and other media reports as a
major cause of the underuse of statins in Switzerland and
encourage us to discuss this topic further. However, deter-
minants of public opinion are beyond the scope of our re-
search article. We are, however, thankful for Romanens et
al. engaging in a discussion about these points and con-
tributing their own perspective to public opinion.
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